• PDF / 169,311 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 52 Downloads / 134 Views

DOWNLOAD

REPORT

---

1 S

Acute kidney injury following off-label use: 8 case reports In a study, 8 patients (3 women and 5 men) aged 41-81 years were described, who developed acute kidney injury (AKI) during offlabel treatment with lopinavir/ritonavir for coronavirus disease 2019 (COVID-19) [routes, dosages, and outcomes not stated]. The patients, who were admitted with COVID-19, were initiated on off-label treatment with lopinavir/ritonavir. None of the patients had chronic kidney disease, however, 0–3 days after the initiation of treatment, all the patients developed AKI. Thereafter, all patients were admitted to the ICU with a sequential organ failure assessment (SOFA) score of 3–12. Out of 8, 6 patients showed proteinuria, whereas 5 patients showed haematuria. Amongst the 8 patients, 7 patients required vasopressor support and 2 patients required dialysis. Eventually, 4 patients died [cause of death not stated]. Binois Y, et al. Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19. Kidney International Reports 5: 1787-1790, No. 803519870 10, Oct 2020. Available from: URL: http://doi.org/10.1016/j.ekir.2020.07.035

0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Dec 2020 No. 1834